Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:47:54.095Z.
Calculation as of: 2026-10-06T16:47:54.095Z.
Quote observation: 2026-10-06T16:43:50.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 49c5230cca2432c6fd0637270100fe2f3d02ebc9238e4fdbb1f4ddcca099658b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
iSpecimen Inc.
Market Cap
$2.67M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| iSpecimen Inc. (ISPC) | $2.67M | N/A |
| Nuwellis, Inc. (NUWE)vs › | $2.61M | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.54M | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.56M | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.58M | N/A |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.45M | N/A |
| Onconetix, Inc. (ONCO)vs › | $2.35M | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.31M | N/A |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.33M | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.04M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
